Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 31

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 31
---
 subsequent stockholder meetings,
the Company shall cause an additional stockholder meeting to be held every ninety (90) days thereafter. Holding such additional stockholder
meetings can be time-consuming, divert management’s attention and resources, and cause us to incur significant expenses.

<div align='center'>20</div>

Interest of Certain Persons in Matters to Be Acted Upon

When you consider our
Board’s recommendation to vote in favor of this proposal, you should be aware that our directors and executive officers and
existing stockholders may have interests that may be different from, or in addition to, the interests of other of our stockholders.
In particular, Iroquois Capital Investment Group, LLC (“ICIG”), which beneficially owns more than 5% of our voting
securities, and its affiliate Iroquois Master Fund Ltd. (“IMF”), participated in the Offering. Additionally, 3i, LP
(“3i”), Five Narrow Lane LP (“Five Narrow”) and Alto Opportunity Master Fund, SPC-Segregated Master
Portfolio B, together with its affiliates (“Alto”), beneficially own more than 5% of our voting securities and
participated in the Offering. ICIG, IMF, 3i, Five Narrow and Alto may be unable exercise all of the Series Warrants issued
to them in connection with the Offering if this proposal is not approved by our stockholders. ICIG and IMF, together, and 3i, Five
Narrow and Alto may, by virtue of the issuance of the Series Warrant Shares to which each is entitled upon exercise of their
respective Series Warrants at the initial exercise price, acquire rights to a majority of the voting power of us, based on the
number of shares of Common Stock outstanding as of the Record Date.

Required Vote

The affirmative vote of the
holders of a majority of the stock having voting power present by virtual attendance or represented by proxy at the Special Meeting and
entitled to vote on the Issuance Proposal is required to approve the Issuance Proposal. “ABSTAIN” votes will have the same
effect as votes cast “AGAINST” the Issuance Proposal. Because the Issuance Proposal is not considered a routine matter, your
bank, broker, trustee or other nominee, as the case may be, will not be able to vote your shares without your instruction with respect
to the Issuance Proposal. As a result, the failure to instruct your bank, broker